Evidence map›Paper›PMID 33829411›Full record

ArticleNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2021

CD200 Immune-Checkpoint Peptide Elicits an Anti-glioma Response Through the DAP10 Signaling Pathway.

Elisabet Ampudia-Mesias, Francisco Puerta-Martinez, Miurel Bridges, David Zellmer, Andrew Janeiro, Matt Strokes, Yuk Y Sham, Ayman Taher, Maria G Castro, Christopher L Moertel and 2 more

Erratum issuedOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Elisabet Ampudia-Mesias *Department of Pediatrics, University of Minnesota, Minneapolis, MN, 55455, USA.
Francisco Puerta-Martinez *Department of Molecular and Computational Biology, University of Southern California, Los Angeles, CA, 90089, USA.
Miurel BridgesBioinformatics and Computational Biology Program, University of Minnesota, Minneapolis, MN, 55455, USA.
David ZellmerDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, 55455, USA.
Andrew JaneiroDepartment of Molecular and Computational Biology, University of Southern California, Los Angeles, CA, 90089, USA.
Matt StrokesCell Signaling Technology, Inc, Danvers, MA, 09123, USA.
Yuk Y ShamBioinformatics and Computational Biology Program, University of Minnesota, Minneapolis, MN, 55455, USA.
Ayman TaherDepartment of Neurosurgery and Department of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, MI, 48109, USA.
Maria G CastroDepartment of Neurosurgery and Department of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, MI, 48109, USA.
Christopher L MoertelDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, 55455, USA.
G Elizabeth PluharMasonic Cancer Center, University of Minnesota, Minneapolis, MN, 55455, USA.
Michael R OlinDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, 55455, USA. olin0012@umn.edu.ORCID http://orcid.org/0000-0001-5322-7688
University of Minnesota · USUniversity of Michigan · USUniversity of Southern California · USCell Signaling Technology (United States) · US

Funding

Training in PharmacoNeuroImmune Substance Abuse ResearchT32DA007097 · NIDA · UNIVERSITY OF MINNESOTA TWIN CITIES · PI MOLITOR, THOMAS WILLIAM · 1985 to 2021
$13.1M
Project 2: Cell Migration in Mechanically Complex MicroenvironmentsU54CA210190 · NCI · UNIVERSITY OF MINNESOTA · PI LARGAESPADA, DAVID ANDREW, ODDE, DAVID J. · 2016 to 2020
$10.0M
Immune-suppressive Myeloid Cells in the Glioma Microenvironment: Signaling Mechanisms and Novel Therapeutic StrategiesR37NS094804 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CASTRO, MARIA G · 2015 to 2021
$2.9M
Crosstalk between glioma cells & immune cells in the tumor microenvironment: TherR01NS074387 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CASTRO, MARIA G · 2011 to 2015
$1.9M
HDL-Loaded Nanoparticles for Glioma TherapeuticsR21NS091555 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CASTRO, MARIA G · 2015 to 2016
$427k
NCI NIH HHS U54 CA210190NIDA NIH HHS T32 DA007097NINDS NIH HHS R01 NS074387NINDS NIH HHS R21 NS091555NINDS NIH HHS R37 NS094804
6 · The paper itself

Abstract

Numerous therapies aimed at driving an effective anti-glioma response have been employed over the last decade; nevertheless, survival outcomes for patients remain dismal. This may be due to the expression of immune-checkpoint ligands such as PD-L1 by glioblastoma (GBM) cells which interact with their respective receptors on tumor-infiltrating effector T cells curtailing the activation of anti-GBM CD8

Indexed as

Amino Acid SequenceAnimalsAntigens, CDAntineoplastic AgentsBrain NeoplasmsFemaleGenetic TherapyGliomaImmune Checkpoint InhibitorsMembrane GlycoproteinsMiceMice, Inbred C57BLMice, KnockoutProtein Structure, TertiaryReceptors, ImmunologicSignal TransductionAntigens, CDantigens, CD200Antineoplastic AgentsCD200 receptor, mouseHcst protein, mouseImmune Checkpoint InhibitorsMembrane GlycoproteinsReceptors, ImmunologicCD200ARGBMImmune checkpointsImmunotherapyPhase 1

Identifiers

PMID33829411
PMCPMC8609078
OpenAlexW3143710785

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.